Phase II ALCANTRA Trial of Blinatumomab in Relapsed/Refractory Ph-Positive B-Precursor ALL


Phase II ALCANTRA Trial of Blinatumomab in Relapsed/Refractory Ph-Positive B-Precursor ALL
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Martinelli G et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: Results from a Phase 2 single-arm, multicenter study (ALCANTARA). Proc ASH 2015;Abstract 679.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.